The Hedgehog (Hh) cascade controls cell proliferation, differentiation and patterning of tissues during embryogenesis but is largely suppressed in the adult. The Hh pathway can become reactivated in cancer. Here, we assimilate data from recent studies to understand how and when the Hh pathway is turned on to aid the neoplastic process. Hh signaling is now known to have a role in established tumors, enabling categorization of tumors based on the role Hh signaling plays in their growth. This categorization has relevance for prognosis and targeted therapeutics. In the first category, abnormal Hh signaling initiates the tumor. In the second category, Hh signaling helps maintain the tumor. In the third category, Hh signaling is implicated but its role is not yet defined.
Hedgehog (Hh) signaling in cancer
The orderly process of development depends upon wellorchestrated signals. These signals transform a single cell into a complex multicellular organism. Incredibly, in spite of the complex end result, the transformation employs relatively few types of signals, including Wnt, Notch, transforming growth factor-b, fibroblast growth factor and Hedgehog (Hh). These secreted protein signals direct cell proliferation, cell fate determination, epithelial-tomesenchymal transitions and the rearrangement of cells by motility and adhesion changes. The processes used to build organs and tissues during development are highly relevant to cancer (Figure 1 ). Mounting evidence suggests that tumors hijack normal developmental pathways for their own growth; by activating a single signal transduction pathway, tumors can grow, recruit a blood supply and invade adjacent tissues. In this review, we first focus on how Hh signaling contributes to normal organ development and then we describe how the reawakened Hh cascade drives the initiation, growth, invasion and maintenance of tumors associated with these organ systems.
Hh signaling was first described in the context of cell fate determination and patterning of the fruit fly, Drosophila melanogaster [1] . The core components of the Hh pathway that were delineated in Drosophila are conserved in mammals ( Figure 2 ) [2] . The basic signaling cascade consists of a series of repressive interactions, with each protein holding the next in check, until the transcription of a still mostly unknown array of target genes is affected. In the absence of Hh pathway activity, these target genes are actively repressed. When secreted Hh binds to its receptor Patched (Ptc/PTCH), the inhibition of Smoothened (Smo/SMOH), a G-protein-coupled receptor that activates downstream intracellular components of the pathway, by Ptc is relieved. The transcription of target genes (including Ptc and Gli) is subsequently activated by the Gli family of transcription factors [3] . The resultant genetic program forms and organizes many tissues and organ systems during embryogenesis.
The role Hh plays in the growth of tumors can be classified according to how the pathway is activated [4] . These mechanisms include loss-of-function mutations in inhibitory proteins such as Ptc1, gain-of-function mutations in positive regulators such as Smo and overexpression of the Hh ligands, leading to autocrine or paracrine activation of the pathway and renewal of cancer stem cells ( Figure 3 ). Hh signaling was first linked to cancer when a mutation in PTCH, the gene encoding PATCHED1, was found to cause Gorlin syndrome, a rare genetic disorder characterized by tumor formation in the skin (basal cell carcinoma, BCC), cerebellum (medulloblastoma, MB) and soft tissue (rhabdomyosarcoma, RMS) [5] [6] [7] . Loss of one copy of PTCH is sufficient to cause the syndrome; germline mutation of both copies is presumed fatal based on mouse models [6] [7] [8] . In the tumors, both copies of the gene are often inactivated [9] . In the late 1990 s, most sporadic BCCs were found to have hyperactivated Hh signaling [7] . Subsequently, mutations
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Corresponding author: Scott, M.P. (mscott@stanford.edu). TRMOME-616; No. of Pages 12 in other Hh pathway components, including hyperactivating mutations of SMO [10] and loss-of-function mutations in Suppressor of fused (SUFU), have been discovered in BCC [11] . Activating Hh pathway mutations can cause sporadic MB [12] . As is typical in other developmental pathways, activating components of the pathway are potential protooncogenes that promote tumor growth when overactive, whereas restraining components of the normal pathway are tumor suppressors that allow tumor growth if they are damaged ( Figure 1 ). Following initial findings that the Hh pathway plays a role in rare cancers, aberrant Hh pathway activation has been observed in numerous other cancers ( Figure 1 ). It has been speculated that Hh plays a role in tumors responsible for over a third of cancer deaths [13] .
Development provides a context for understanding tumorigenesis; as Hh signaling plays a different role in the formation of each tissue, the effect of abnormal Hh signaling might have different implications for each type of cancer. In this review, we classify tumors by when Hh becomes important for the neoplastic process ( Figure 4 ). For each class of tumors, we describe Hh signaling during normal development of the tissue and then we discuss how Hh signaling contributes to tumorigenesis in that same tissue. The first category includes tumors in which a mutation in the Hh pathway initiates tumorigenesis; examples of this type include MB and BCC. The second category includes cancers where Hh signaling does not initiate tumorigenesis but contributes to tumor growth; this category includes colon cancer and pancreatic cancer.
The final category, the unclassified group, includes cancers where the Hh pathway has been implicated, but its exact role remains a mystery; an example of this class is lymphoma. Finally, we discuss future challenges in tumor biology as they relate to Hh signaling.
Category 1 cancers: Hh signaling is important for tumor initiation and maintenance
Gorlin syndrome is caused by the loss of one functional copy of PTCH [7] , which activates the Hh signaling pathway. Several mouse models of Hh pathway activation were engineered and studies in these mice have revealed that constitutive Hh signaling alone is sufficient to form BCC, RMS and MB. Activating the Hh pathway at any of several levels of the signal transduction cascade including SMOH, SUFU and GLI or in conjunction with inactivation of additional tumor-suppressor genes leads to the formation of these tumors [15, 16] . A large proportion of sporadic BCC and a subset of MB and RMS harbor activating mutations of Hh pathway genes [7, 10, 17, 18] . These findings implicate activating Hh pathway mutations as initiating events in tumorigenesis.
Skin development and BCC
Skin is the largest organ in the body, acting as a barrier to protect against external insult and to regulate internal temperature and water balance. Skin is composed of stratified layers of epithelia; the deepest stratum consists of a single layer of cells that continually proliferate to replace outer terminally differentiated cells that are sloughed off. Tissues where Hedgehog activity is important for normal development and can play a role in their conversion to tumors. Activating components of the Hh pathway support normal development of the organs and tissues indicated, but are potential proto-oncogenes that promote tumor growth in those same tissues when overactive. Restraining components of the normal Hh pathway also support development, but function as tumor suppressors that allow tumor growth if they are damaged in adulthood. This schematic depicts the array of tissues in which Hh supports development and can promote tumorigenesis. Colors denote the role Hh plays in the formation of the tumors: red is category 1, yellow is category 2 and green is category 3.
During embryogenesis, skin is formed from epithelial stem cells that are guided by a series of epithelial-mesenchymal interactions to become the epidermis as well as the associated hair follicles and glandular structures [19] .
One signal important for the formation of the hair follicle is Sonic hedgehog (Shh), one of three mammalian Hh ligands. During normal hair development, Shh is expressed in the epithelial placode and its receptor Ptc is expressed in the underlying dermal condensate. Shh signals through Ptc, inducing epidermal proliferation and invagination to form a hair follicle. Mice with forced expression of Shh in the skin have abnormal epidermal proliferation, whereas mice lacking Shh fail to develop normal epithelial invaginations during hair follicle development [20] [21] [22] . In the adult, hair follicles cycle continuously through periods of active growth (anagen), regression (catagen) and quiescence (telogen) [23] . Reactivation of follicle growth in the adult is regulated by the same signals important for follicle formation during embryogenesis: cyclic production of Shh drives the hair follicle cycle. Increased Shh expression and activation of Hh target genes induces resting hair follicles to enter anagen, with consequent hair growth [24] . Once the hair follicle is regenerated, Shh expression is shut down and Hh targets are turned off.
Because the skin is constantly exposed to and damaged by the environment, it is the site of the most common cancer, BCC [25] . Although the prevalence is high, the death rate from this type of cancer is very low because these tumors rarely metastasize. Untreated BCC can cause significant local tissue destruction and, for those that develop metastatic disease, it can be difficult to cure [26] . Morphologically, BCCs resemble hair follicles and are thought to arise from the abnormal proliferation of the cells that normally form the hair follicle [27] .
Aberrant Hh signal transduction is thought to be the pivotal abnormality in BCC. Activating mutations in the Hh pathway can lead to BCC. More than 90% of sporadic BCCs have mutations in one allele of PTCH and an additional 10% have activating mutations in SMOH [28] . Mutations identified in PTCH and SMOH presumably arise from UV radiation and overactivate the Hh pathway [22, 26] . Mice heterozygous for Ptc develop BCC after the deletion of the wild-type allele [22, 29] . Constitutively active Smo produces BCC in mice [29] , and mice heterozygous for SuFu, a negative regulator of the Hh pathway, can also develop BCC [10] . Activating the transcriptional effectors Gli1 or Gli2 can lead to BCC [30, 31] . Mouse models have shown us that the magnitude of Hh target gene activation often correlates with the severity of the tumor phenotype in skin [32] .
Constitutively active Hh signaling induces Wnt/b-catenin signaling in BCC and this is required for tumor formation [31, 33] . Similar to Hh, Wnt/b-catenin is important for hair follicle development and cycling. The Wnt signaling pathway initiates hair bud formation and is required for the subsequent Hh signaling that results in proliferation of the epithelium to form the mature follicle [31] .
Although surgery is the mainstay of BCC treatment, new pharmacologic therapies have emerged from understanding disease pathology [6, 33] . SMO inhibitors are one exciting advance [34] and some of these inhibitors are being tested in clinical trials. In a recently reported clinical trial, GDC0449 (Genentech-Curis, San Francisco, CA, USA) showed antitumor activity in locally advanced or metastatic BCC that had Hh overactivity. Of 33 patients in the study, 18 had an objective response to GDC0449, according to assessment by imaging and/or physical examination. Of the patients who had a response, two had a complete response and 16 had a partial response. The other 15 patients had either stable disease (11 patients) or progressive disease (4 patients) [35] .
The primary cilium, a tiny hair-like projection on the surface of most cells that is important for Hh signaling, has been recently implicated in BCC and MB tumorigenesis [36, 37] Cilia have both activating and inhibitory roles in modulating Hh pathway activity: a role that depends on the level at which the pathway is mutated. Because of the dual role of primary cilia in these tumors, these microantennae are not yet clear candidates for pharmacologic manipulation as therapeutic targets. Therapeutic advances will probably come as we develop a better understanding of the role of primary cilia in Hh signaling.
Cerebellum development and MB
Normal cerebellum development requires formation and organization of five classes of cerebellar neurons. Cerebellar granule neurons (GNs) are the most abundant type of neuron in the brain, with each mouse brain containing approximately 10 8 GNs. In the mouse, immature GNs proliferate in the external germinal layer (EGL) of the cerebellum and, in the first 3 weeks following birth, a large pool of GN precursors (GNPs) is generated on the surface of the developing cerebellum. Ptc1 restrains proliferation of GNPs until Shh is secreted by Purkinje neurons to activate the pathway and target gene expression [38] . Shh-dependence of GNP proliferation within the EGL was established by in vivo and in vitro studies [39] . Following this period of proliferation, GNPs exit the cell cycle and become mature GNs [39, 40] . The events that control the transition between GNP proliferation and GN maturation remain unclear [39, 41] .
MB, a tumor that arises from overproliferating GNPs, is the most common malignant brain tumor in children [15, 41] . Many children with MB survive, but they often suffer long-term cognitive and psychosocial impairment as a result of standard treatment, a regimen of radiotherapy and chemotherapy [41, 42] . The consequences of current therapies underscore the importance of understanding tumorigenesis in MB and thus better therapies that specifically target pathways important for tumor formation can be developed.
Mutations that reduce the restraints on the Hh pathway in GNPs lead to MB. Reducing the dose of PTCH by half produces persistent expression of Hh target genes, including those that support cell division and tumorigenesis. Ptc1 heterozygous mice, which have approximately 50% of Ptc1 transcript relative to wild-type mice, show increased Shh target gene expression and unregulated GNP proliferation [42] . Hyperproliferative GNPs form preneoplastic lesions on the surface of Ptc1+/mouse cerebellums; these lesions are not found in wild-type mice [43, 44] . Most of these lesions are transient; detectable GNP foci persist only on the cerebellar cortical surfaces of the approximately 15% of mice that are developing or have developed MB tumors by 3 months of age [45] .
Neoplastic progression in MB remains incompletely understood. Although constitutive Hh pathway activation in Ptc1 heterozygous mouse MB lesions is well documented, Ptc1 haploinsufficiency is not sufficient for neoplastic transformation, given the low penetrance of MB in mice heterozygous for Ptc1 [43, 44] . An additional mutation, resulting in constitutive Shh target gene activation, is required to release GNPs from the antiproliferative influence Ptc1. Given that Ptc1 is a tumor-suppressor gene, one clear candidate for a possible ''second hit'' to promote tumorigenesis is the second copy of Ptc1. Data support inactivation of the second Ptc1 allele and ensuing loss of heterozygosity as a mechanism for MB tumorigenesis [45] , but other mutations leading to neoplastic progression of early lesions might also contribute [9, 16] . The primary cilium, a subcellular organelle important for proper Hh pathway signaling, has been recently implicated as the ''second hit'' in MB and BCC tumorigenesis [17, 37] . Development of therapeutic strategies to disrupt Hh signaling in MB has benefited from the use of both mouse models and resected tissue from human MB. Inhibition of SMOH blocks proliferation in resected human MB tumors and prevents formation of MBs in mouse models [38] . In GNPs, Smo antagonists induce a gene expression profile consistent with reduced proliferation and enhanced differ-entiation. This result was encouraging; however, because of the importance of Hh in normal bone development the mice treated with Smo antagonist suffer from irreversible defects in bone structure. Second-generation Hh-pathway inhibitors including a small-molecule inhibitor of Gli1 are currently being tested [46] .
GDC0449, the SMO inhibitor tested in BCC, was used to treat a 26-year-old man with metastatic MB that was refractory to treatment [46] ; rapid regression of the tumor and reduction of symptoms were observed, but the effectiveness of the therapy was transient owing to rapidly acquired drug-resistance mutations in SMOH [47] . These clinical results highlight the promising future of rationally designed targeted therapy as well as its challenges. Studies of Hh signaling in normal cerebellum development have highlighted the importance of Hh signaling in this brain region and have informed strategies for treatment of MB. Bone growth complications that arise after systemic Hh pathway blockade in mice underscore the importance of further study to elucidate the role of Hh in development and neoplasia of other viscera.
Muscle development and RMS
The Hh pathway is critical for many epithelial-mesenchymal interactions in development and plays an important role in myogenesis: the formation and specification of muscle [48] . Myogenesis occurs after muscle precursor cells have been specified, in part by expression of muscle regulatory and myocyte enhancer factors [35] . Hh is a regulatory signal for the induction of muscle-specific genes and expansion of muscle progenitor populations during embryogenesis [49, 50] . Although normally turned off in adult musculature, Hh is reactivated during regeneration of adult skeletal muscle after an injury [51, 52] .
Unrestrained Hh activity, for example after Ptc1 loss, can lead to RMS [51] . RMS is the most common soft-tissue sarcoma in the pediatric population, accounting for up to 10% of solid pediatric malignancies [51] . Morphologically, RMS resembles skeletal muscle and is classified into two subtypes with varied tumor locations and ages of presentation. Staging and treatment of RMS depends on tumor size, spread and effectiveness of resection [50] . Although most RMS occurs sporadically, it sometimes associates with human Gorlin syndrome and the mouse Ptc1 haploinsufficiency model of Gorlin syndrome [52, 53] . RMS tumors have a variety of genetic and molecular abnormalities, some of which are useful for accurate prognosis or the identification of biological subtypes [53] . Most alveolar RMS tumors have translocations that create PAX3-FKHR or PAX7-FKHR fusion genes as well as PTCH imbalances [15] . In addition to the Gorlin syndrome model, manipulation of PAX and FOX genes coupled with combinatorial activation of known oncogenes and inactivation of known tumor-suppressor genes leads to RMS in mouse models [19, 54, 55] . Despite these models, little is known about the underlying genetic changes that cause a developing skeletal muscle cell or a mesenchymal progenitor cell to transform into invasive malignant RMS. RMS development in the Ptc1 haploinsufficiency mouse model indicates that Hh pathway deregulation can give rise to MB, but other mouse models demonstrate that Hh pathway deregulation is not the only determinate of RMS tumorigenesis. Category 2 cancers: Hh signaling is important for maintenance but not initiation of the tumor In category 2 cancers, Hh signaling does not play a role in tumor initiation but instead is important for tumor maintenance and growth. Examples of category 2 tumors include colon cancer and pancreatic cancer. In both, Hh signals derived from the stroma are important for maintaining proliferation of tumor cells.
Colon cancer
The gastrointestinal tract forms from two germ layers, the endoderm and mesoderm, and is innervated by cells arising from the ectoderm. Data from Shh and Indian hedgehog (Ihh) knockout mice show that folding of the primitive gut tube into the complex adult intestine depends on paracrine Hh signals between the epithelial cells and the surrounding mesenchyme [55, 56] . As the primitive gut tube forms, it develops villi, finger-like projections of the small intestine, by upward growth of the underlying mesenchyme. In a similar manner, epithelial folds form in the large intestine. Early in development, Shh and Ihh are diffusely expressed throughout the endoderm [57, 58] . The identity of the cells that express and those that receive the Hh signal remains controversial. Experiments to clarify these interactions are difficult because cellular targets of Hh signaling are stage-specific during development. One current hypothesis is that the villi and epithelial folds form when Shh expression is restricted to the area that eventually becomes the base of these folds, where cells differentiate to become glandular crypts. The restriction of Shh expression inhibits epithelial proliferation to allow normal crypt development by growth of the flanking epithelium.
A recent study profiled Hh pathway activity in the mouse from embryonic day (E) 10.5 to adult in murine antrum, pyloric region, small intestine and colon [38] and reported that paracrine Hh signaling occurs throughout the gastrointestinal tract during embryonic and adult life [58] . Mice lacking Shh cannot form the invaginated surface of the intestine and instead have overgrown epithelium [38, 59] . Ihh knockout mice have decreased numbers of hypoplastic villi compared to wild-type animals, and they do not have an enteric nervous system, which results in the dilation of their colon [59, 60] . Hh signaling plays an important role in the radial patterning of the developing colon, including regulation of smooth muscle formation and proper rotation of the entire system [61] . The adult colon has low level Shh expression at the base of the crypts [55, 62] . The distal colon accumulates Ihh at the tips of the differentiated colonic enterocytes. Ptc1 is expressed in the mesenchyme underlying the Ihh-positive cells, suggesting that the direction of signaling in the adult is similar to that of the developing embryo [55, 62] . Recent data implicate Hh signaling in patterning processes such as formation of the pyloric sphincter and active modulation of villus core smooth muscle [54] .
Shh, Ptc1 and Smo are expressed in human and mouse hyperplastic polyps, adenomas and adenocarcinomas of the colon [54] . Furthermore, the growth of colon cancer cell lines in vitro is inhibited by cyclopamine, an inhibitor of the Hh pathway. Both of these findings suggest that Hh acts in an autocrine manner in colon cancer. These data have recently been criticized; the cyclopamine inhibitor studies have been repeated with doses of cyclopamine that restrict the effects of this drug to Smo, and at these doses it does not inhibit proliferation of colon cancer cell lines [59, 63] . An alternative hypothesis based on normal development has been proposed; colon cancer cells overproduce Hh ligands that signal to the surrounding nonmalignant mesenchyme to release a mitogen, which acts on the cancer cells, closing the paracrine loop. Inhibiting the Hh pathway in the stroma with an oral antagonist, an antibody or by genetic deletion inhibits the growth of human colon cancer xenografts [60] . Hh target gene activity peaks in epithelial cells of human colon carcinomas at the time of metastatic spread [64] . Although the paracrine role of the Hh pathway in colon cancer is well documented and is supported by its role in development, an additional role of the Hh pathway in cancer stem cells cannot be ruled out at this time, even though it has not been formally demonstrated [65] .
Aberrant Hh pathway activity could drive colon cancer growth indirectly by activating the Wnt pathway [63] . Wnt is important during early gut development as b-catenin promotes the formation of the gut endoderm and its adoption of an intestinal fate. In concert with Hh, activation of Wnt is required for proper formation and maintenance of the villi and crypts. Accumulation of b-catenin in the nucleus, a hallmark of active Wnt signaling, occurs in intestinal crypts [66] . Mouse studies reveal that deletion of Tcf4, which encodes an activator of Wnt target gene transcription, prevents development of intestinal crypt progenitor cells [63, 67] . Overexpression of oncogenic forms of b-catenin or mutation of a negative Wnt pathway component adenomatous polyposis coli (APC) results in hyperproliferation of the epithelium [68, 69] . The Wnt pathway is active in up to 90% of hereditary and sporadic colon cancers [70, 71] .
The Hh pathway can inhibit the Wnt pathway [72] . When either Shh or Ihh is inhibited, the Wnt target genes Engrailed-1 and bone morphogenetic protein-4 (BMP-4), which are normally restricted to the crypt, become widely expressed throughout the intestinal epithelium and might increase epithelial proliferation. Loss of Hh ligands could activate the Wnt pathway in colon cancer. Ihh expression is absent, for example from adenomatous polyps in patients with familial adenomatous polyposis [67] . Gli1 negatively regulates Wnt signaling by suppressing nuclear accumulation of b-catenin [69] . If Shh suppresses Wnt activation, the reason for the apparent overlap of Shh and nuclear bcatenin expression in the intestinal crypts is not clear. The answer could be elucidated by additional immunohistochemistry and imaging studies.
Although the importance of Hh signaling to the progression of colon cancer remains controversial, clinical trials have already begun. Based on preclinical data from xenograft mouse models as well as Phase I trials, GDC0449 is being tested in a Phase II clinical trial as therapy for metastatic colon cancer (www.clinicaltrials.gov). Interfering with a pathway that is not an inherent oncogenic driver of the tumor but that mediates the interaction of cancer with its environment might work in a manner similar to inhibitors of angiogenesis, effectively halting tumor growth but not preventing its initiation. Given that Hh appears to be important for the normal regeneration of the intestinal crypts, it will be important to determine if inhibiting the Hh pathway affects normal intestinal turnover and response to injury.
The Hh pathway is critical for the normal development of the colon and its role in colon cancer is beginning to be defined. It is clear that there is a paracrine loop of Hh signaling that is reactivated during the progression of colon cancer, but it is not yet clear if the Hh pathway plays additional roles to promote colon cancer growth such as promoting the survival of cancer stem cells. Inhibitors of the Hh pathway are currently being investigated as novel antitumor agents in colon cancer; however, their efficacy is not yet known.
Pancreas development and cancer
Hh signaling is crucial for the development of the pancreas [59, 71] . Approximately 95% of the pancreas consists of exocrine cells that produce digestive enzymes, whereas the remainder consists of small clusters of endocrine cells important for the production of various hormones, including insulin. The adult pancreas is formed by the fusion of two primitive pancreatic buds, a ventral bud that ultimately forms the pancreatic head and uncinate process, and a dorsal bud that ultimately forms the pancreatic tail. Pancreas development depends upon signaling between the mesoderm and two regions of ventral and dorsal foregut endoderm. The endoderm uniformly expresses Shh and Ihh until approximately E8.5. A transient drop in the expression of Shh allows formation of the dorsal pancreatic bud and contributes to the formation of the ventral pancreatic bud. The loss of Hh signaling required to form the pancreas is supported by studies in Xenopus; when an mRNA encoding constitutively active Smo is injected into Xenopus embryos, they lack a pancreas [73, 74] . Mouse embryos exposed to cyclopamine form ectopic pancreatic tissue throughout the intestine [75] . In the adult human, IHH, PTCH and SMO are localized in pancreatic endocrine tissue and might foster insulin secretion [58, 76] . Shh expression is absent in adult pancreas [77, 78] . Inhibiting Hh signal transduction in hamster pancreatic ductal cells reduces cell growth, suggesting that Hh is important for normal pancreatic regeneration [79, 80] .
Pancreatic cancer is the fourth most common malignancy in the United States, with 30 000 new cases diagnosed each year [74] . The bleak landscape of pancreatic cancer therapy is highlighted by the deaths of approximately this same number of pancreatic cancer patients each year [81] . A large body of literature suggests that activated Hh target genes drive human pancreatic adenocarcinoma [76] . Primary human tumor specimens and tumor cell lines have high levels of GLI1 and PTCH1 [78] . Inhibiting Hh signaling using cyclopamine can inhibit the growth of a subset of human pancreatic cancer cell lines in vitro or in xenograft models [60, 76] . Cyclopamine can even inhibit growth of cell lines derived from aggressive metastatic tumors, suggesting that in spite of their aggres-sive behavior, the tumors are still dependent on Hh signaling for growth [64] . Overexpression of Shh in the mouse pancreas causes PanIN lesions similar to early human pancreatic neoplasms in morphology and genetic changes (e.g. Her2/Neu amplification, Ras mutations) [60, 82] . A mouse engineered for inducible expression of a dominantly active Gli2 develops undifferentiated invasive tumors [64, 83] . When dominant-active Gli2 is expressed in the pancreatic epithelium in combination with constitutively active Ras, extensive PanIN lesions and invasive pancreatic tumors with reduced latency of onset are observed [60, 83] . This research strongly suggests that a subset of pancreatic cancers is driven by Hh signaling and that this pathway is an attractive target for therapy.
Hh signaling in pancreatic cancer has been studied in detail and appears to occur in a paracrine manner, although initial studies suggested an autocrine pathway [80] . Initial studies demonstrated that pancreatic tumors have high levels of Hh target gene transcription, as measured by Ptc1 mRNA, compared with adjacent normal tissue [82] . This hypothesis has recently been discarded for one that proposes a paracrine loop that recapitulates normal pancreatic development. Two reasons account for this change: first, the dose of cyclopamine used to inhibit pancreatic cell lines has off-target effects [63, 82] , and second, the Hh pathway is not active in the pancreatic tumor cells [64, 65] Increased Ras activity, an early change in the progression to pancreatic adenocarcinoma, drives Hh ligand production in the pancreatic tumor cells [65, 83] . The increased production of the Shh ligand by the tumor cells compared to normal cells activates the Hh pathway in surrounding nonmalignant stromal cells. The effect of Hh on the surrounding stoma leads to both a paracrine mitogen feedback loop to the pancreatic tumor cells as well as preventing the development of a vasculature in the stroma [83] . This leads to a dense avascular stroma typical of human pancreatic cancer. Hh inhibitors in genetic mouse models of pancreatic adenocarcinoma normalize the vasculature, allowing the delivery of coadministered chemotherapy and improved treatment outcomes [83] . Inhibiting the Hh pathway also inhibits the growth of human pancreas cancer xenografts [63, 83] .
In summary, the Hh pathway plays a role in the formation of the pancreas but becomes less prevalent in the adult pancreas. During the formation of pancreatic adenocarcinoma, Ras is a critical switch that turns on the expression of Shh in the tumor cells. The Hh ligand signals to the surrounding stroma to create a dense avascular environment. The stroma in turn sends an as yet unknown feedback signal to the pancreatic tumor cells to support their growth.
Category 2 tumors include cancers that rely on Hh signaling to provide a proliferative signal once the tumor has formed, but Hh pathway activity does not initiate tumor formation. Now we turn to tumors that could eventually be added to this category. is not well defined. Many cancers fall into this category and include lymphoma, breast cancer, ovarian cancer, esophageal cancer, liver cancer and lung cancer. We include prostate cancer in this category owing to residual controversy in the field; however, data from Wade Bushman's laboratory as well as multiple mouse models presented in abstract form and at meetings demonstrate a paracrine model for the Hh pathway in prostate cancer, which would support categorization in category 2.
Hematopoiesis and lymphoma
During development Hh ligands play numerous roles in the initiation and growth of hematopoietic cells [78] . Ihh released from stromal cells activates hematopoiesis and supports growth of developing hematopoietic cells [84] . In adults, Hh ligands are thought to be important for the renewal of hematopoietic stem cells [65, 85] . Shh produced by follicular dendritic cells of the lymph node is important for survival, proliferation and antibody production by B cells [86, 87] , and Shh can regulate proliferation of T cells as well as cytokine release [88, 89] .
The ligands Ihh and Shh promote survival of B-cell malignancies such as lymphoma [90, 91] . Unlike solid tumors, which produce Hh ligand, Ihh and Shh are produced by surrounding nonmalignant cells in the bone marrow, spleen and lymph nodes to allow growth of lymphoma cells. These tissues serve as the equivalent of a stem cell niche, nourishing the production of dividing cells. In a c-Myc-driven mouse model of Burkitt's lymphoma, lymphoma cells from the transgenic mice undergo apoptosis in the absence of their surrounding microenvironment unless they are grown in the presence of Shh or Ihh [92, 93] . This suggests that the stroma provides a prosurvival signal to the tumor cells in the form of Hh ligands or other factors for which production is controlled by Hh ligands. It is suggested that activating Hh target genes in lymphoma might increase production of prosurvival factors such as Bcl-2 and Bcl-xL. Supporting this hypothesis, inhibition of the Hh pathway with cyclopamine induced apoptosis of cultured primary lymphoma cells and reduced Bcl-2 transcription. Cyclopamine-induced cell death did not occur in tumor cells that, despite the cyclopamine, overexpress Bcl-2 [93, 94] .
Another study documented the importance of Hh signaling in mantle cell lymphoma (MCL), an aggressive subtype of B-cell lymphoma [94] . Transcripts of genes encoding the Hh pathway components Ptc, Smo, Gli1 and Gli2 were overproduced in primary MCL cells and MCL cell lines. The growth of one of the MCL cell lines in culture was partially responsive to exogenous Shh; growth of this same cell line was inhibited by addition of cyclopamine in the absence of Shh. Reduction of Gli1 or Gli2 mRNA with antisense oligonucleotides decreases the viability of four cell lines and increased their susceptibility to chemotherapy (doxorubicin)-induced cell death, although the effect of the antisense oligonucleotides, with or without chemotherapy, is minimal. MCL cells have increased Bcl-2 and cyclin D1 protein expression. Reduction of Gli1 or Gli2 mRNA minimally decreases the amount of Bcl2 and cyclin D1 transcripts. It was hypothesized that in MCL overproduction of Gli1 and Gli2 proteins might increase Bcl-2 and cyclin D1 protein production and consequently increase cell survival. How the Gli genes are induced and when in MCL development they increase has not been reported.
Dysregulated Shh signaling might also be important for T-cell malignancies. One group demonstrated that Shh but not Gli1 is amplified in anaplastic lymphoma kinasepositive anaplastic large-cell lymphoma tumors and cell lines [93] . Inhibition of Shh signaling with cyclopamine or silencing of Gli1 expression with RNA interference decreased viability of these lymphoma cells [94] .
Prostate development and cancer
The Hh pathway is important for prostate gland patterning and development. The prostate exocrine gland operates in the male reproductive tract after developing through steps of epithelial branching [95] . Shh and Ihh are made by the fetal urothelium and, as in many viscera, Hh signaling influences proliferation and differentiation, including budding of prostatic ducts and stromal development [96] . In mice, the level of Hh signaling declines as the organ matures and remains at low levels into adulthood [97] . In contrast to the low levels of Hh signaling in adult mice, significant Hh target gene transcription occurs in the adult human prostate [98] . The levels of Hh pathway activity into adulthood directly correlate with the expansion of glands and stroma of the prostate that occurs in benign prostatic hyperplasia and prostatic carcinoma [99] .
Whether Hh signaling is important for prostate cancer remains controversial [99, 100] . Prostate cancer results from a multistep process that begins with a circumscribed noninvasive low-grade nodule composed of morphologically normal glands and progresses to an infiltrating higher grade adenocarcinoma, composed of atypical glands that infiltrate the surrounding prostatic and urothelial tissue. In advanced human prostate cancers, Hh target gene expression is high [100, 101] . Autocrine Hh signaling by prostate tumor cells could be a mechanism for their continued proliferation and invasive behavior, but some recent studies found no evidence of autonomous or paracrine signaling in human prostate cancer cell lines using luciferase-based assays of target gene activation and analysis of Hh target gene transcript levels [100, 102] . Hh pathway activation alone is insufficient for development of prostate carcinoma. Constitutive activation of Hh target genes by an activated allele of Smoothened in postnatal prostate epithelium did not cause tumor formation or any prostatic abnormality in 12-month-old mice [48] . Hh pathway activity could contribute to sustained growth of prostate carcinoma, but further work is needed to define the role of Hh, if any, in this cancer.
Lung development and cancer
Lung development begins with budding from the primitive foregut, followed by branching and bronchopulmonary segment formation. The next phase involves branching of ducts into terminal bronchioles and formation of an epithelial-lined airway conducting system, then additional branching of the bronchioles and angiogenesis within the mesenchyme. The later terminal sac and alveolar phases of development form the adult lung with fully mature alveoli Review Trends in Molecular Medicine Vol.xxx No.x TRMOME-616; No. of Pages 12 [101, 102] . In mature lung, respiratory epithelium covers the trachea, bronchi, bronchioles and distal alveolar units. Multiple cell types including basal cells, alveolar cells and neuroendocrine cells are present in the lung. During development, all three Hh ligands control patterning of pulmonary airways from bronchi to alveolar sacs [103] . In the pseudoglandular phase of lung development, Shh is a spatial signal for bronchiole patterning. Shh is produced by the epithelium at the far tips of bronchioles and is received by the surrounding mesenchyme [61] . Gli genes are expressed in mesoderm surrounding bronchi and the trachea [104] [105] [106] . Disruption of Gli3 or Shh genes causes lung morphology abnormalities [107] .
Respiratory epithelium repair and lung cancer associate with increased activation of Hh pathway target genes. Mature respiratory epithelium is regenerated at a very slow rate unless injured by toxins or smoking [108, 109] . When injury does occur, it results in repair, proliferation and partial reconstitution of cell populations that regenerate the respiratory epithelium [110] . Tobacco smoking introduces toxic mutagens into the lung and is responsible for >80% of lung cancer, a common malignancy that carries a poor prognosis [110] . Because lung damage and consequential repair process expands precursor populations, it is probable that repair processes induced by smokingrelated damage coupled with mutagenic effects of smoking result in a predisposition to lung cancer [105] . Lung injury elevates Shh, Gli and Ptc mRNA in the epithelium [105, 111] .
Primary lung cancer is classified as small cell (SCLC) or non-small cell lung cancer (NSCLC). SCLC and NSCLC associate with activated Hh target genes [105] . Both lung cancers are commonly diagnosed late in the course of the disease, underscoring the importance of understanding tumor initiation and developing effective therapeutic options [112] . Approximately 80% of primary lung cancer is NSCLC [113] . In a recent screen of 60 human lung cancer cell lines with a Hh antagonist, a subset of NSCLC cell lines overexpressed Hh and Hh target genes [114] . Some groups have reported that NSCLC cell lines express Hh as well as key Hh target genes, consistent with Hh acting through an autocrine mechanism [114] [115] [116] . SCLC is highly associated with smoking and comprises approximately 20% of lung carcinomas [114] . Some types of SCLC have morphology reminiscent of a Hh-regulated phase of epithelial differentiation during airway development [113] . Hh regulated genes are active in a subset of human SCLC cell lines. In these lines, inhibition of Smo with cyclopamine suppresses growth in vitro and in xenograft models [63, 110] . Others have not observed any correlation between Hh antagonist-mediated growth inhibition and Hh pathway target gene expression in human SCLC and NSCLC cell lines [65, 114] . In spite of the uncertainty surrounding the role of Hh in lung cancer, clinical trials are in progress using the Hh inhibitor GDC0449 [114] .
Other cancers
Additional tumors can be characterized as category 3 but are not covered in this review; these include esophageal cancer, liver cancer, breast cancer and ovarian cancer. Although Hh signaling plays an important role in the development of many of these tissues and there are examples of pathway dysregulation in tumors, the precise role of Hh signaling in tumorigenesis remains unclear.
Category 3 cancers include those where the Hh pathway is active but its role in the initiation and growth of the tumor is not well defined. With further research, these tumors could be reclassified as category 1 or category 2. Alternatively, study of category 3 tumors might reveal additional strategies by which the Hh pathway supports tumor growth.
Concluding remarks
In the same way that developmental biology has been unified by near-universal molecules, genes and signaling pathways, cancer biology has been refined by the recognition of changes in signaling pathways including Hh that give tumor cells the properties they require to grow. Hh signaling is sufficient to trigger cancer in cells where Hh signaling is normally necessary for growth and development. Presumably cells that comprise mature tissues, which relied upon Hh signaling for development, already possess the additional gene activities that are needed to grow in response to Hh signals, and genes that counteract Hh growth signals are off. Category 1 cancers occur in tissues where Hh normally regulates cell division, such as cerebellum and skin. In category 2 cancers, mutations in the Hh pathway are not sufficient for tumorigenesis. There could be several reasons to explain this: in these cell types, Hh target genes might not include genes involved in cell division, other genes that block mitogenesis by Hh might be active or cofactors that act in concert with Hh target genes to stimulate growth could be absent, inactive or inaccessible.
Despite the inability of Hh to start tumorigenesis in the cells of origin for category 2 tumors, Hh signaling can still make the cancer worse. A recent study of pancreatic, colorectal, brain and breast tumors employed full-genome sequencing to identify the genetic changes in the tumors [65] . In pancreatic tumors, a dozen pathways or processes are affected; some mutations affect properties such as invasiveness or homophilic cell adhesion, whereas others activate pathways including Wnt, Notch, TGFb, c-Jun Nterminal kinase and Hh. Presumably, the activity of each of these pathways confers advantageous properties for growth and survival to cells, the worst type of ''evolution'' for the afflicted patient.
It will be important and fascinating to learn exactly how Hh target genes add to the malignant properties of the transformed cells. Identification of targets will inform therapy. Will the targets be general to all cells where Hh signaling is activated or to only particular tissues? What properties of normal cells are under the control of Hh signaling, and how does that regulation contribute to events during tumorigenesis? We can look forward to important insights about which target genes are important for the contributions of Hh signaling to each of the various types of cancer. We can also expect to learn how specific Hh targets confer important properties to normal cells, such as the ability to migrate, altered surface properties or the production of specialized proteins. Understanding the underlying biology of cancer will help scientists to under-stand which target genes underlie which cell properties. Understanding the detailed molecular mechanism of mammalian Hh signaling will lead to the development of further novel and specific therapies for these lethal cancers. The development of several Hh pathway inhibitors coupled with an understanding of the categories outlined here can guide the strategic use of Hh pathway inhibitors to affect tumor progression and patient prognosis. In all but category 1 tumors, Hh pathway blockade alone will be insufficient to cure the cancer. This underscores the importance of thoughtfully employing Hh pathway antagonists as adjuvant therapeutic agents, depending on the role of Hh in a given cancer.
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